Options with increasing volume: NYMX MYL ULTA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand
August 29, 2016 6:06 AM EDTMylan N.V. (Nasdaq: MYL) announced that its U.S. subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton... More
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore
August 25, 2016 11:46 AM EDTEvercore ISI affirms Mylan (Nasdaq: MYL) with a Hold rating and $49 price target amid today's EpiPen cost-adjustment news.
The firm commented, Thanks to our top rated Specialty Pharma guru Umer Raffat (and CNBC) we are highlighting a slide Mylan is featuring (see below) in its... More
